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ABSTRACT
The study and application of human pluripotent stem cells (hPSCs) will be enhanced by the avail-
ability of well-characterized monoclonal antibodies (mAbs) detecting cell-surface epitopes. Here,
we report generation of seven new mAbs that detect cell surface proteins present on live and
fixed human ES cells (hESCs) and human iPS cells (hiPSCs), confirming our previous prediction
that these proteins were present on the cell surface of hPSCs. The mAbs all show a high correla-
tion with POU5F1 (OCT4) expression and other hPSC surface markers (TRA-160 and SSEA-4) in
hPSC cultures and detect rare OCT4 positive cells in differentiated cell cultures. These mAbs are
immunoreactive to cell surface protein epitopes on both primed and naive state hPSCs, providing
useful research tools to investigate the cellular mechanisms underlying human pluripotency and
states of cellular reprogramming. In addition, we report that subsets of the seven new mAbs are
also immunoreactive to human bone marrow-derived mesenchymal stem cells (MSCs), normal
human breast subsets and both normal and tumorigenic colorectal cell populations. The mAbs
reported here should accelerate the investigation of the nature of pluripotency, and enable
development of robust cell separation and tracing technologies to enrich or deplete for hPSCs
and other human stem and somatic cell types. STEM CELLS 2017;35:626–640
SIGNIFICANCE STATEMENT
This manuscript describes the production and characterization of seven new monoclonal anti-
bodies. These antibodies are significant because they enable new explorations of human plurip-
otent stem cells. The antibodies should be useful for gaining a better understanding of human
pluripotency, enriching for human pluripotent stem cells, removing pluripotent stem cells, and
also for performing similar functions with subsets of human breast and colon tissue.
INTRODUCTION
Human ESCs [1] and iPSCs [2, 3] have revolution-
ized the possibilities for cell-based regenerative
therapies, but there are few in vitro diagnostic
approaches that facilitate quality control of live
human pluripotent stem cells (hPSCs) and their
derivatives. Refinement of such approaches is
an essential requirement for the safe and effec-
tive translation to diagnostic and therapeutic
applications of hPSC-derived cell types [4, 5].
Strategies ranging from cytotoxic and proapop-
totic chemicals [6–10] to cell-surface biomarkers
are being used to remove undifferentiated
hPSCs from lineage-differentiated cells [11, 12].
Monoclonal antibodies (mAbs) are especially
useful because of their sensitivity and specificity.
However, many of the conventionally used cell
surface markers for hPSCs are not reactive with
proteins, but instead recognize complex carbo-
hydrate or lipid moieties for which there are no
identified corresponding genes [13]. Some of
the markers used for characterization of hPSC
lines are also immunoreactive in mature cell
types, so are useful only within a limited time
frame of hPSC culture [11]. In recent years,
there have been additional markers developed
that are reported to be highly specific for detect-
ing hPSC surface proteins or glycans [14–19] but
few of these are directed against known pro-
teins. Having a variety of antibodies would be
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useful for purifying conventionally cultured hPSCs that are line-
age primed, akin to mouse epiblast-derived cells [20, 21], dis-
play heterogeneity and have been demonstrated to contain cell
populations that express varying levels of pluripotency-
associated markers [19, 22–28]. Moreover, availability of new
pluripotency cell-surface markers will aid investigation of the
distinctive naive state that has been recently described for
human PSC cultures [29], a state more similar to the ground
state of inner cell mass (ICM)-derived mouse ESCs [30]. There-
fore, strategies using new cell-surface markers to investigate
human pluripotency, to help resolve the heterogeneity that
occurs with in vitro hPSC culture, as well as to stringently detect
and eliminate all undifferentiated cells from enriched differenti-
ated populations would be extremely valuable to the field.
MATERIALS AND METHODS
Informed Consent
All work using hPSCs was carried out in accordance with appro-
vals from Monash University and the CSIRO Human Research
Ethics Offices or by the full UCLA Institutional Review Board and
the UCLA Embryonic Stem Cell Research Oversight Committee.
Human breast tissue (pathologically normal) from reduction
mammoplasty surgeries was donated by consenting individuals
through the Victorian Cancer Biobank under the approval of the
WEHI and Melbourne Health Human Research Ethics Commit-
tees. Human normal colon and colorectal cancer tissues were
resected from consenting individuals through the Cabrini Hospi-
tal under the approval of the Cabrini Human Research Ethics
Committee.
Animal Care
Protocols and use of animals in this project were undertaken with
approval of the Monash University Animal Welfare Committee
following the Australian Code for the Care and Use of Animals for
Scientific Purposes (8th Edition 2013) and the Victorian Preven-
tion of Cruelty to Animals Act and Regulations legislation.
HPSC Culture and In Vitro Differentiation
Undifferentiated, karyotypically normal MEL1 [31], WA09 [1]
(H9, WiCell Research Institute, Madison, WI, http://www.
wicell.org) human ES cell (hESC) lines and hiPS-PDL-D1C6 [32],
hiPS-NHF1.3 [33] human iPS cells (hiPSC) lines were routinely
maintained on a monolayer (1.2 3 104 cells/cm2) of mitotical-
ly inactivated mouse embryonic fibroblasts (MEFs) in hPSC
medium comprised of Dulbecco’s modified Eagle medium:nu-
trient mixture F-12 (DMEM/F12, 1:1), 20% v/v knockout
serum replacement (KOSR), 2 mM Glutamax, 1% v/v modified
Eagle’s medium (MEM) nonessential amino acids (NEAA), (all
from Life Technologies, Carlsbad, CA, http://www.lifetechnolo-
gies. com), supplemented with 10 ng/ml human basic fibroblast
growth factor (bFGF, Merck Millipore, Billerica, MA, http://
www.merckmillipore.com). For some experiments hPSC lines
were grown in Essential E8 Medium on a Geltrex Matrix (all
from Life Technologies) [34, 35].
Cells were cultured (378C/5% CO2 in air) to 70%-80% con-
fluence with daily hPSC media changes then passaged using
300 U/ml Collagenase I (Worthington Biomedical Corp., Lake-
wood, NJ, http://worthington-biochem.com) in DMEM/F12,
(0.5 mM EDTA for Essential E8 cultures), washed and replated
at dilutions of 1:4-1:10. Nondirected in vitro differentiation of
hPSC cultures was performed using an embryoid body (EB) meth-
od as previously described in detail [36]. EBs were collected fol-
lowing 7, 14, and 28 days of differentiation for flow cytometric
analyses as described below. A routine hPSC maintenance culture
provided a day 0 control for each differentiation time course
analysis.
To investigate mAb detection of naive state pluripotent
cells, hiPSCs were generated from two different human adult
dermal fibroblast (HDF) cell lines (Life Technologies, C-013-5C:
1528526, 569390), using the Cytotune II kit (Life Technologies)
according to the manufacturer’s instructions, and cultured ini-
tially in the standard hPSC culture conditions described above
and then in three different chemically defined culture media
reported to reset cells to a naive phenotype. The media used
were Naive Human Stem Cell Medium (NHSM) [37], 5i/hLIF
medium supplemented with FGF and Activin A (5i/L/FA) [38]
and RSeT medium (StemCell Technologies, Vancouver, Canada,
http://www.stemcell.com), all of which have been reported to
successfully culture naive state hPSCs [37, 38]. Additionally,
mAb detection using a human embryonic stem cell line
UCLA20n [39] derived using 5i/L/FA medium was investigated.
To harvest undifferentiated (primed and naive) hPSC cul-
tures and differentiated EBs for flow cytometric analyses and
fluorescence activated cell sorting (FACS), cultures were
washed twice with Dulbecco’s phosphate buffered saline (PBS)
without calcium and magnesium (CMF-PBS) and dissociated to
single cell suspensions using TrypLE Express (all from Life
Technologies) in 5-8 minute (hPSCs) or 15-30 minute (EBs)
incubations (378C/5% CO2 in air) with gentle pipetting. Single
cell harvests were washed twice in DMEM/F12, resuspended
in FACS buffer (as below) and kept on ice for immunolabeling.
Somatic Human Cell Preparations
Human bone marrow-derived MSCs (hBM-MSCs) were sourced
and propagated from cryopreserved stocks (Lonza, PT-2501,
Basel, Switzerland, http://www.lonza.com) cultured on tissue
culture flasks coated with Geltrex Matrix (Life Technologies)
according to manufacturers’ instructions in MSC Growth Medi-
um comprised of low glucose DMEM, 2 mM L-Glutamine, 1 mM
sodium pyruvate, 1% v/v antibiotic/antimycotic comprising 100
U/ml penicillin, 100 mg/ml streptomycin, 25 mg/ml amphotericin
B (all from Life Technologies), supplemented with 20% v/v fetal
bovine serum (FBS), (Sigma-Aldrich, St. Louis, MO, http://www.
sigmaaldrich.com). A complete media change was performed
every 3-4 days and the cells were passaged at90% confluence.
Human BM-MSCs were were maintained at 378C in a humidified
atmosphere containing 5% CO2. Human mammary cell prepara-
tions were prepared as previously described [40] and were cryo-
preserved until required for immunostaining and flow
cytometric analyses. For intestinal cell preparations, normal and
cancerous human colorectal tissues were incubated, respective-
ly, with a 3 mM EDTA-0.25 mM DTT solution at 48C for 45
minutes or a 0.125 mg/ml dispase-1 mg/ml collagenase (Sigma-
Aldrich) solution at 378C for 30 minutes. Following subsequent
washes with CMF-PBS and centrifugation, both normal and can-
cer cells were dissociated in TrypLE Express (Life Technologies)
supplemented with 10 lM Rock inhibitor (Y-27632, Abcam,
Cambridge, UK, http://www.abcam.com) and DNAse 1 (Sigma-
Aldrich) for 2 minutes at 378C.
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Antigen Generation
From our previously published list of genes predicted to express
cell-surface proteins on hPSCs [25], 40 candidate immunogens
were selected for which antibodies were not commercially avail-
able at the time, or for which available antibodies could not
detect the native protein for both live and fixed hPSCs by FACS
and immunocytochemical (ICC) analyses (data not shown). The
domain structure for selected hPSC membrane protein candi-
dates was analyzed using the UniProt KnowledgeBase database
(http://www.uniprot.org/) and antigens generated for the larg-
est extracellular domain. Briefly, peptide synthesis (Auspep,
http://www.auspep.com.au) was used to generate immunogens
for small transmembrane domain proteins (<50 amino acids),
building fragments of 19-30 amino acids with no internal cyste-
ine and predicted hydrophilicity, antigenicity, and surface proba-
bility. For medium (50-200 amino acids) and large (>200 amino
acids) domain proteins, corresponding coding regions, incorpo-
rating a C-terminal Flag epitope tag, were synthesized by PCR,
and cloned into mammalian expression vectors for transfection
and transient expression in suspension-adapted 293Freestyle
cells (Life Technologies). Recombinant antigens were purified
from scaled cultures by immunoaffinity and size exclusion chro-
matography. Gene identifier and amino acid sequence of targets
for the seven mAbs described below are given in Supporting
Information Table S1.
Hybridoma Derivation and Culture
Hybridomas specific to hPSC antigens were generated at the
Monash Antibody Technology Facility (MATF, Monash University,
Melbourne, Australia, https://platforms.monash.edu/matf/).
Briefly, CD1 mice were injected intraperitoneally with peptide
or recombinant protein antigen corresponding to the selected
target proteins. Following an ELISA serum titre confirmation,
mice received a prefusion boost immunization using irradiated
MEL1 hES cells, prior to isolation of B cells from the spleen and
fusion to SP2/0 Ag-14 mouse myeloma cells. Hybridomas were
subjected to limited dilution in 96-well plates (1,920 wells per
fusion) and propagated for 13 days in Hybridoma medium (HM)
comprised of high glucose DMEM, 2 mM Glutamax, 1% v/v
penicillin-streptomycin (all from Life Technologies), supple-
mented with 20% v/v FBS (HyClone, GE Healthcare Life Sciences,
Chicago, IL, http://www.gelifesciences.com) and 1% v/v HybER
murine IL-6 (SSI Diagnostica, Hillerød, Denmark, http://www.ssi.
dk/ssidiagnostica). Hybridoma supernatants were collected and
initially screened by direct solid-state antigen microarray assay
(ArrayJet, Tecan, M€annedorf, Switzerland, http://www.tecan.
com) to identify hybridomas generating IgG antibodies binding
each immunization protein. Array-positive supernatants (up to
300 per target antigen) were immunolabeled and screened by
flow cytometry using a LSRII flow cytometry analyzer equipped
with a high throughput 96-well plate module option (BD Biosci-
ences, San Jose, CA, http://www.bdbiosciences.com). Hybrido-
mas corresponding to live hPSC detection were expanded in HM
medium/20% v/v FBS/1% v/v HybER and subclones raised from
single cells robotically sorted for individual 24-well plate culture
(Tecan). Supernatants from clonal cultures were again immuno-
labeled and screened to confirm detection of live hPSCs by flow
cytometry (see Supporting Information Fig. S1A). Parental and
subcloned hybridoma cultures were expanded in HM medium/
20% v/v FBS, passaging at subconfluence each 2-4 days and
eliminating HybER IL-6 in a stepwise manner. Cells were cryopre-
served in HM/20% v/v FBS with 1% v/v DMSO (Sigma-Aldrich)
and stored in vapor phase nitrogen.
Purification of mAbs
To purify and concentrate antibody produced from subcloned
hybridomas, cell cultures were expanded to confluence in
175 cm2 tissue culture flasks (Greiner Bio-One GmbH, Fricken-
hausen, Germany, https://www.gbo.com) in HM medium with-
out the addition of penicillin-streptomycin and with a stepwise
reduction of FBS from 20% v/v to 2.5%-10% v/v, switching to an
ultra-low IgG FBS (Life Technologies) prior to the exhaustion of
cultures. Supernatants were separated from cells by centrifuga-
tion, passed through a 45 mm filter (Sartorius Stedim Biotech,
Goettingen, Germany, https://www.sartorius.com), and aliquots
taken for isotyping (IsoStrip, Roche, Basel, Switzerland, http://
www.roche,com) and repeat confirmation of live hPSC detection
by FACS (see Supporting Information Fig. S1A). mAbs were puri-
fied from these culture supernatants. Briefly, IgG fractions were
isolated by affinity chromatography using mAb Select Sure
recombinant protein A and protein G sepharose HP columns (GE
Lifesciences). Purified mAbs were concentrated using an Ultra-
15 centrifugal concentrator (Merck Millipore), then further
purified by size exclusion chromatography on a Superdex 200 pg
16/60 column (GE Lifesciences) and concentrated as above, in
CMF-PBS containing 0.02% v/v azide. Purified mAb proteins
were analyzed by SDS-PAGE (see Supporting Information
Fig. S1B) under both nonreduced and reducing conditions on
4%-12% BisTris NuPAGE gels (Life Technologies).
Antibodies
All mAbs generated as well as commercially available primary,
conjugated and secondary antibodies used in this study are
listed in Supporting Information Table S2.
Immunostaining (Live and Fixed Cell) and Flow
Cytometry
Undifferentiated hPSC, differentiated EB, human mammary and
hBM-MSC cell preparations were resuspended in cold FACS buffer
comprised of either DMEM/F12 or CMF-PBS supplemented with
10% v/v FBS (Sigma-Aldrich) and for intestinal cell preparations,
CMF-PBS supplemented with 2 mM EDTA, 2% v/v FBS, and 10 lM
Rock inhibitor (Y-27632). Mammary cell suspensions were blocked
with 10% v/v FBS, 0.1 mg/ml DNAseI, and anti-CD16/CD32 Fcg III/II
receptor antibody for 10 minutes at 48C prior to staining. Cell sus-
pensions were aliquoted for fluorescent labeling reactions including
unstained cells, isotype and single color fluorophore controls, keep-
ing all tubes on ice during hybridoma supernatant, antibody and
lectin labeling procedures, and prior to flow cytometry and FACS
analyses. Extracellular, intracellular, single, andmulticolour immuno-
labeling reactions and FACS analyses were all performed as previ-
ously described [11, 40–43]. Briefly, cells were labeled for 30
minutes with hybridoma supernatants or purified mAbs raised to
GPR64, CDCP1, F11R, DSG2, CDH3, NLGN4X, PCDH1 both singly and
in combination with other cell-surface markers CD9, SSEA-3, SSEA-
4, TRA-1-60, GCTM-2, and biotinylated Ulex Europaeus Agglutinin I
(UEA-I) lectin (see Supporting Information Table S2). Cells were next
washed in FACS buffer and incubated for 30 minutes with conjugat-
ed fluorophore isotype matched secondary antibodies or streptavi-
din, again washed and resuspended in FACS buffer supplemented
with 0.1% v/v propidium iodide (Sigma-Aldrich) for the exclusion of
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nonviable cells at analysis. HPSCs were also immunostained for
murine CD90.2, human TRA-1-85, EpCAM, or OCT4 to exclude MEF
cells from FACS analyses except where MEFs expressing green fluo-
rescent protein were used, and hBM-MSCs were immunostained
for human CD90 for phenotype validation. Note, for the first step
biotinylated UEA-I labeling, the FACS buffer was replaced with a 5%
v/v ultrapurified BSA in Hank’s Buffered Saline Solution (HBSS), (Life
Technologies), for all wash steps and for diluting the streptavidin flu-
orophore to avoid potential reactivity between UEA-1 and serum
glycoproteins, or streptavidin with biotin. For OCT4 multicolor anal-
yses, cells were sequentially live cell immunostained for cell-surface
markers followed by fixation, permeabilization and intracellular
immunostaining with anti-human OCT4, as previously described in
detail [11, 42].
Immunostained mammary cells were further washed,
blocked in 5% v/v mouse serum, 5% v/v rat serum (Sigma-
Aldrich), 0.1 mg/ml DNAseI, 1 mg/ml rat immunoglobulin, and
anti-CD16/CD32 Fcg III/II receptor antibody for 10 minutes then
immunostained with conjugated primary antibodies EpCAM-
Pacific Blue (Clone VU1D9), CD49f-PECy7 (Clone GoH3), CD45-PE
(Clone H130), CD31-PE (Clone WM59), and CD235a (Clone GA-
R2) prior to resuspension in propidium iodide as above. Mamma-
ry cell subsets were delineated by FACS analysis, gating for a via-
ble CD312CD452CD235a2 population to exclude hematopoietic
and endothelial cells, then EpCAM and CD49f to yield luminal
progenitor (CD49f1 EpCAM1), mature luminal (CD49f2
EpCAM1), MaSC and basal (CD49f1 EpCAM2), and fibroblast-
enriched stromal (CD49f2EpCAM2) cells. Intestinal cells were fur-
ther immunostained with conjugated primary antibodies EpCAM-
BV421 (Clone EBA-1), CD31-BV510 (Clone WM59), and CD45-
BV510 (Clone HI30). For FACS analysis of gut samples we gated in
on intestinal epithelial cells by selecting EpCAM1 cells while
excluding contaminating endothelial (CD311) and hematopoietic
(CD451) cells.
All fluorescently labeled cell suspensions were filtered
through a 40-mm filter mesh (BD Biosciences) and resuspended
in relevant FACS buffer prior to performing multiple color analy-
ses on a LSRII flow cytometry analyzer (BD Biosciences). Spectral
compensation for auto and nonspecific fluorescence to deter-
mine fluorophore positive and negative cell populations was
performed as previously described [11]. FACS fractionation and
replating of viable cells to colony-forming assays (see below)
was performed using Influx and FACSFortessa instruments (BD
Biosciences). For investigating mAb detection of cells in the
GCTM-2/CD9 coexpression gradient found in hPSC cultures [23],
hPSCs triple-labeled for mAb/GCTM-2/CD9 detection were ana-
lyzed using a FACS Diva Instrument (BD Biosciences) calibrated
and gates set for GCTM-2/CD9 negative and high coexpression
populations as previously described [23, 41]. Flow cytometric
data was generated with instrument software (BD Biosciences)
and analyzed using FlowJo software (Tree Star Inc.).
ICC Staining and Imaging
hPSC cultures harvested using Collagenase I (colony clump) or
Accutase (Life Technologies), (single cell) dissociation were cul-
tured in sterile Multitest 12-well (8 mm diameter) glass slide
chambers (MP Biomedicals, Santa Ana, CA, http://www.mpbio.
com) preseeded with MEF feeder cells and maintained in hPSC
medium as described earlier. At subconfluence cultures were
rinsed with CMF-PBS, fixed with ice-cold absolute ethanol for 5
minutes and air-dried at room temperature, prior to storing at
2208C or directly proceeding to immunolabeling reactions.
Fixed hPSCs were incubated for 30 minutes at room tempera-
ture in blocking buffer comprising CMF-PBS supplemented with
10% v/v goat serum (Life Technologies). Cells were then incubat-
ed with the new purified mAbs against GPR64, CDCP1, F11R,
DSG2, CDH3, NLGN4X, PCDH1 as well as SSEA-3, TRA-1-60,
GCTM-2, and CD9 antibodies diluted in blocking buffer for 60
minutes at room temperature, washed twice in CMF-PBS, then
incubated with secondary Alexa Fluor conjugated antibody(s)
diluted in blocking buffer, for 60 minutes at room temperature.
Immunostained cells were washed twice in CMF-PBS, nuclear
counterstained for 5 minutes in 4’,6-diamidino-2phenylindole
(DAPI), (Sigma-Aldrich, 10 ng/ml in CMF-PBS) and mounted in
Vectashield (Vector Laboratories, Burlingame, CA http://www.
vectorlabs.com). For the intracellular OCT4 immunostaining,
cells were first stained with extracellular antibodies and then
sequentially with the mouse anti-human OCT4 antibody (Merck
Millipore) diluted in blocking buffer, (see Supporting Informa-
tion Table S2 for details of primary and secondary antibodies
used). Fluorescence was observed using an Olympus BX51
inverted microscope and images captured using a Nuance multi-
spectral imaging system 3.0.2 (Perkin Elmer, Waltham, MA
http://www.perkinelmer.com). HPSC bright field colony images
were taken using a Motic AE2000 light microscope and Motic
Images Plus 2.0 software (Motic, Hong Kong, http://www.motic.
com).
Colony-Forming Assays
HPSC colony-forming assays were performed in 12-well (3.8 cm2/
well) tissue culture plates (BD Biosciences) as previously described
[41] with the following modifications. HPSCs were immunolabeled
with antibodies and lectin then fractionated by FACS, replating to
culture cells from the top 25% of mAb-fluorochrome positive
events gated against isotype and unstained hPSC controls. Cells
were plated per triplicate at a density of 5,000 cells per well and
cultured in hPSC medium on supporting MEFs as described above.
Colonies formed were counted manually on day 5 on a Nikon
Eclipse Ti microscope and cultures harvested enzymatically on day 7
and prepared for intracellular OCT4 immunolabeling and flow
cytometry analyses as described above.
RNA Sequencing
RNA was extracted using the RNeasy Micro Kit (Qiagen, Hilden,
Germany, https://www.qiagen.com), according to the manufac-
turer’s instructions, from 2-3 3 104 FACS-purified hPSCs per
sample. For the generation of sequencing libraries, 25 ng of
RNA (RIN value >9) was subjected to SPIA amplification
(NuGen). Two biological replicates per culture condition were
sequenced using the HiSeq 2000 sequencing platform (Illumina,
San Diego, CA, http://www.illumina.com). The targeted number
of sequencing reads per sample was 30 million (50 bp single
reads). RNA-seq samples were deposited at the NIH Short Reads
Archive (www.ncbi.nlm.nih.gov/sra), accession numbers
SRP093689, SRP094406, and SRP094408.
Bioinformatic Analysis
Sample sequencing reads were aligned to the human genome
(complete hg19 [UCSC version, July 2007]) using Tophat2 (v 2.0.13,
default parameters [44]). Transcript quantification was performed
using HTSeq (v 0.6.1, default parameters [45]). Differential gene
expression analysis was performed using limma [46] and edgeR
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[47]. In summary, library size was normalized using voom [48], line-
ar models were fit to transcripts and differential gene expression
assessed using eBayes moderated t statistic. Significantly differen-
tially expressed genes were selected on the basis of an absolute
Log2 expression value of 1 and p< .05, adjusted for multiple test-
ing to control false discovery rate using Benjamini and Hochberg’s
method [49]. Normalized gene expression array values from naive
and primed cells of Theunissen’s et al. (2014) study were extracted
from Supporting Information Table S1 of the published report [38].
To compare array expression values versus RNA-seq counts,
platform-specific effects were removed using limma’s remove-
Batcheffect function on logarithmic base 2 transformed values.
ELISA
Purified mAb detection for each corresponding immunogen to
which hybridomas were initially raised was confirmed by ELISA,
except for anti-hGPR64 which was raised to a peptide immuno-
gen. A 96-well microplate (R&D Systems, Minneapolis,
MN, http://www.rndsystems.com) was prepared with 100 ml of
1 mg/ml purified antigen protein per well and incubated over-
night at 48C. Anti-hCDCP1 (20 mg/ml), anti-hF11R (4 mg/ml),
anti-hDSG2 (3 mg/ml), anti-hCDH3 (20 mg/ml), anti-hNLGN4X
(20 mg/ml), anti-hPCDH1 (20 mg/ml) were added to correspond-
ing antigen coated wells (100 ml/well), and the antigen-mAb
cross-linking detected using secondary antibody (100 ml/well),
Alexa Fluor488 conjugated goat anti-mouse IgG (Life Technolo-
gies) at 1:500 dilution. The fluorescent measurement was moni-
tored using the Enspire 2300 Multilabel Reader (Perkin Elmer)
at 488 nm and 519 nm for excitation and emission, respectively.
Data Analysis
All experimental assays (except where noted) were performed
in triplicate at a minimum on biologically discrete cell samples.
All data with error bars represent SEM, unless otherwise stated.
RESULTS AND DISCUSSION
Target Selection and Generation of mAbs
To generate tools for detecting cell-surface proteins on viable
hPSCs that correlate with the presence of the pluripotency-
associated transcription factor OCT4 [50], we selected candidate
genes that we identified from our FACS-based GCTM-2/CD9
immunotranscriptional profiling of hPSCs [25]. The workflow to
obtain mAbs to these targets is outlined in Figure 1A. Briefly, we
analyzed the protein domain structures for candidate markers
and generated antigens via peptide synthesis or by protein
expression in modified HEK293 cells for 30 cell-surface proteins
for which antibodies were either not commercially available at
the time, or were available but did not detect epitopes on live
hPSCs by flow cytometric analyses (data not shown). Following
immunization with antigens and the generation of hybridomas,
culture supernatants were screened by robotic solid-state antigen
array analyses for detection of the corresponding immunogen
and then via high-throughput flow cytometry to confirm capabili-
ty for detecting live hPSCs (Supporting Information Fig. S1A). Of
the 200-300 hybridomas typically screened for each candidate
protein, we observed that fewer than 10% subsequently detected
cell-surface protein on live hPSCs. Clonally expanded mAbs puri-
fied from hybridoma cultures (Supporting Information Fig. S1B)
were further characterized in this study.
New mAbs Detect Defined Cell Surface
Proteins on HPSCs
mAbs were raised against the following seven human recombi-
nant proteins; CUB domain containing protein 1 (anti-hCDCP1),
platelet F11 receptor (anti-hF11R), desmoglein 2 (anti-hDSG2),
cadherin 3 (anti-hCDH3), neuroligin 4X-linked (anti-hNLGN4X)
and protocadherin 1 (anti-hPCDH1) and against a synthetic pep-
tide sequence for G protein-coupled receptor 64 isoform 4
(anti-hGPR64), (Table 1 and Supporting Information Table S1).
Antibodies were tested for their detection of live cells in undif-
ferentiated hPSC cultures (see Fig. 2A). ELISA analyses (Fig. 1B)
confirmed that the mAbs specifically detect each of the target
cell-surface proteins to which they were initially raised. ICC
staining of fixed hPSCs (Fig. 1C) demonstrated that each of the
newly generated mAbs displayed cell surface staining in undif-
ferentiated cultures of MEL1 hESCs that were costained with
OCT4, but not in the supporting mouse embryonic fibroblast
(MEF) feeder cells (not shown). This staining is comparable to
that observed for pluripotency-associated markers TRA-1-60
and CD9 (Fig. 1C). For the anti-hGPR64 mAb we observed the
same strong cell surface staining as for the other mAbs for live
hPSCs (Fig. 1C) but less consistently for fixed cell staining,
suggesting that fixation alters the epitope recognition sequence
for the peptide antigen to which this mAb was raised.
To determine the broader utility of the new panel of purified
mAbs we carried out a series of experiments using the following
cell lines; MEL1 and WA09 (hESC lines) [1, 31], hiPS-PDL-D1C6
and hiPS-NHF1.3 (hiPSC lines generated via lentiviral and episom-
al vector strategies, respectively, [32, 33]) and the hiPS-HDF cell
lines generated in this study (see Materials and Methods). All
mAbs recognized a high proportion of cells from all cell lines fol-
lowing live cell extracellular immunostaining and flow cytometry
(Figs. 2A, 3D and Supporting Information Figs. S2A, S3B). Interest-
ingly, a lesser average proportion of cells was detected by the
anti-hCDH3 mAb for two of the hiPSC cultures (70.25%6 6.99%
hiPS-NHF1.3 and 69.86%6 9.71% hiPS-PDL-D1C6 cells) compared
with that detected for hiPS-HDF32f cell cultures (88.08%6
7.23%) and the hESC lines (87.90%6 5.84% MEL1 and 90.66%
6 5.38% WA09), (Fig. 3D and Supporting Information Figs. S2A,
S3B). This may be due to a higher level of heterogeneity, perhaps
from differentiation, in the NHF1.3 and PDLD1C6 hiPS cell lines.
Note, the seven mAbs also showed similar patterns of immunore-
activity as assessed by flow cytometry on hPSCs grown in Essen-
tial E8 Medium on a Geltrex Matrix (all from Life Technologies)
[34, 35], (data not shown).
New mAbs Show High Correlation with
Immunodetection of OCT4 and Pluripotency-
Associated Antibodies in HPSC Lines
It is widely established that undifferentiated hPSC cultures will
inherently be subject to a low level of spontaneous differentia-
tion and accordingly vary in the percentage of cells showing OCT4
and cell surface marker immunoreactivity among cell lines and
for each passage. We, therefore, determined the correlation of
immunodetection of each mAb with OCT4, TRA-1-60, or SSEA-4
using sequential immunostaining and flow cytometric analyses.
Representative flow cytometric plots are shown for OCT4 double
staining (Fig. 2B) and for TRA-1-60 and SSEA-4 double staining
with each mAb (Supporting Information Fig. S3). Replicate
multicolour flow analyses (presented as bar graphs of mean
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Figure 1. Monoclonal antibodies (mAbs) raised to candidate cell-surface antigens detect epitopes on human pluripotent stem cells (hPSCs). (A): A
schematic overview for the approach used to generate new mAbs capable of recognising hPSC extracellular proteins. Target proteins were identified
from fluorescence activated cell sorting (FACS)-based CD9/GCTM-2 immunotranscriptional profiling of hPSC cultures bioinformatically combined with
membrane polysome translation state array analyses [25], and antigens generated by peptide synthesis or cloning into mammalian expression vectors.
Hybridomas raised and initially validated by solid-state antigen array were screened by high throughput flow cytometry for detection of live hPSCs, pri-
or to cloning, expansion, mAb purification and final validation by detection of live hPSCs by flow cytometry. (B): ELISA fluorescence measurement at
488 nm excitation and emission 519 nm validated specific detection of recombinant antigen immunogens corresponding to purified anti-hCDCP1
(blue bar), anti-hF11R (red bar), anti-hDSG2 (green bar), anti-hCDH3 (purple bar), anti-hNLGN4X (light blue bar), anti-hPCDH1 (orange bar) antibodies
compared with control wells without antigen (blank), secondary antibody only (AF488 only) and BSA protein. Error bars depict SEM, n 5 3. (C): Repre-
sentative images of undifferentiated MEL1 human ES cell cultured on a feeder layer of mouse embryonic fibroblasts in hPSC medium for 4-7 days,
showing surface immunostaining using purified anti-hGPR64, anti-hCDCP1, anti-hF11R, anti-hDSG2, anti-hCDH3, anti-hNLGN4X, anti-hPCDH1 (green,
AF488), merged with 40,6-diamidino-2phenylindole (DAPI) counterstained nuclei (blue) and colocalizing with OCT4-positive cells (red), compared with
CD9, TRA-1-60 (AF488/DAPI), and isotype controls for the fluorochromes AF488 and AF647. All images shown are for fixed cell mAb staining, except
for anti-hGPR64-AF488 that was live cell stained prior to fixation for OCT4 detection. Scale bars5 100 mm. Abbreviations: DAPI, 40,6-diamidino-
2phenylindole; FACS, fluorescence activated cell sorting; hPSCs, human pluripotent stem cells; mAbs, monoclonal antibodies.
percentages for each mAb of human OCT-4 positive cells
detected) confirmed a high correlation for detection of the OCT4
positive cells by each mAb on multiple hPSC lines (Supporting
Information Fig. S2B, S2C), and similarly for hPSCs costained with
each mAb and TRA-1-60 or SSEA-4 (Fig. 2C). Collectively these
results showed a very high level of concordance between staining
for each of the seven new mAbs described herein and OCT-4,
TRA-1-60, or SSEA-4 immunoreactivity. The results also demon-
strated variation in the percentages of cells staining positively for
all antibodies among individual cell populations, highlighting the
necessity for comprehensive live cell characterization of hPSCs to
avoid heterogeneous inputs to cell-based applications, potentially
leading to inefficient differentiation [5, 51].
We and others have shown in previous work that a GCTM-
2neg/CD-9neg subpopulation in hPSC cultures is associated with
the very earliest spontaneous hPSC differentiation and this pop-
ulation does not yield teratomas following in vivo transplant
[23–25, 41, 52]. The variation for each mAb’s immunoreactivity
within this double-negative population is predicted to reflect
how rapidly the corresponding protein epitopes are downregu-
lated during early stage hPSC differentiation. To investigate the
association of our new antibodies with early lineage commit-
ment of hPSCs, we determined the correlation between cell
populations detected by each mAb and the GCTM-2/CD9 profile
of hPSCs (Fig. 2D, i-ii). These analyses (Supporting Information
Fig. S4) revealed that the mAb-positive cell populations over-
lapped with 93.3%6 5.59% of the GCTM-2hi/CD-9hi (undiffer-
entiated) population in MEL1 cultures, except for the CDH3
mAb, which detected an average of 72.50%6 11.71% of cells in
the GCTM-2hi/CD-9hi subfraction. Of interest were the much
greater differences seen among the mAbs in detection of cells in
the GCTM-2neg/CD-9neg gated (early differentiation) population,
with anti-hCDH3 detecting the average lowest number of cells
(4.03%6 2.53%) and anti-hF11R detecting the average highest
number of cells (87.70%6 5.26%). Each mAb will, therefore,
have specific utility as a pluripotency marker in studies seeking
to resolve heterogeneity in undifferentiated hPSC cultures
[26–28] as well as those interrogating in vitro recapitulation [53]
or reprogramming [54] of early developmental events.
New mAbs Enable Cell Sorting to Produce
HPSC Colonies
We next sought to assess the utility of the new panel of
mAbs for applications requiring viable hPSC detection and
downstream culture. Colony-forming assays (CFAs) were per-
formed, to determine retention or loss of self-renewal ability
for hPSC populations detected by live cell FACS for each mAb,
by replating cells gated for the brightest positive quartile
population (mAb[25]%hi) into hPSC culture conditions. Visual
morphological assessment at 5 days postplating confirmed the
robust establishment of self-renewing colonies containing cells
exhibiting typical hPSC appearance of rounded, compact, high
nuclear-cytoplasmic ratio (not shown) from all mAb[25]%hi-
fractionated cells (Fig. 2E, i). Colony numbers ranged from an
average minimum 1196 15 colonies/well for F11R25%hi cells to
an average maximum 2146 23 colonies for DSG225%hi, com-
pared with the widely used hPSC marker TRA-1-60 (1896 16
colonies), the lectin UEA-1 (1646 19 colonies), and unfractio-
nated hPSCs (1516 22 colonies) for the same cultures. Flow
cytometric OCT4 analysis of colony cultures at day 7 (Fig. 2E, ii)
determined that colonies formed from post-FACS replating of
mAb-bright cells contained self-renewing OCT4-positive cells in
percentages greater than that for unfractionated hPSCs, and
comparable to that for UEA-1, TRA-1-60, and SSEA-4.
Naive State Human Pluripotent Cells Express
Antigens Detected by the New mAbs
Recent reports indicate that human PSCs can exist in two
distinct pluripotent states. One state, termed “primed” is
thought to be similar to that of murine postimplantation
epiblast cells [20]. The other state, termed “naive” or “ground
state,” appears to be analogous to ICM-derived murine cells
[21, 55]. Multiple groups have recently reported the genera-
tion of human PSCs from either blastocysts or by somatic cell
reprogramming that bear a naive state phenotype [29, 39].
Further, culture conditions supporting the demonstration of
naive hPSCs from single human ICM cells have recently been
reported [56]. In this study, we asked whether the epitopes
for any of our new mAbs were also detectable in naive states
of pluripotency. We generated hiPSCs by reprogramming
human dermal fibroblast (HDF) cells from two donors
(HDF32f, HDF55f) using standard hPSC culture conditions that
produce lineage primed hiPS cells, then cultured these in pre-
viously described NHSM defined culture conditions [37] 5i/L/
FA [38] and the recently available RSET to convert cells to a
distinct naive cellular state. Immunoreactivity for each mAb
was analyzed on these na€ıve hiPS cultures and also compared
to mAb immunoreactivity on a recently published naive hESC
line (UCLA20n), derived and cultured in the same 5i/L/FA con-
ditions [39]. Figure 3A summarizes the naive hPSC lines used
in this study. RNA sequencing and metadata analyses con-
firmed distinct expression profiles for parental HDFs, primed
and naive hiPSCs (5i/L/FA) that also clustered with published
primed and naive cell data [38] (Fig. 3B, Supporting Informa-
tion Fig. S5). Analysis of selected genes in our cultures dem-
onstrated a high concordance with those reported for primed
Table 1. Human cell surface proteins corresponding to new hPSC monoclonal antibodies
Gene Alternate gene names Common protein names
GPR64 EDDM6, HE6, TM7LN2 G protein-coupled receptor 64 isoform 4
CDCP1 CD318, SIMA135, TRASK CUB domain containing protein 1 isoform 1,
membrane glycoprotein gp140
F11R CD321, JAM, JAM1, JAMA, JCAM, KAT, PAM-1 Junctional adhesion molecule A (JAM-A),
Platelet F11 receptor
DSG2 ARVC10, ARVD10, CDHF5, CMD1BB, HDGC Desmoglein 2 (DSG2); cadherin family member 5
CDH3 CDHP, HJMD, PCAD Cadherin 3 (CDH3), placental cadherin (P-cadherin),
NLGN4X ASPGX2, AUTSX2, HLNX, HNL4X, NLGN4 Neuroligin-4 X-linked (NLGN4X), neuroligin-X
PCDH1 PC42, PCDH42 Protocadherin 1 isoform 1 (PCDH1), cadherin-like protein 1.
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and naive state hiPSCs [38] (Supporting Information Fig. S5).
Morphologically, hiPSC and hESC cultures maintained in each
of the NHSM, 5i/L/FA and RSeT conditions, all displayed the
domed morphology typically described for naive-like pluripotent
cells (Fig. 3C). The new panel of mAbs detecting cell surface epito-
pes in our primed hESC and parental HDF-iPS cultures also dem-
onstrated heterogeneity in detection of corresponding epitopes
in the undifferentiated naive hiPSC cultures from the different
culture methodologies (Fig. 3D). Interestingly the percentage of
naive state hiPSC or hESC displaying positive immunoreactivity to
four mAbs (hGPR64, hCDH3, hNLGN4X, & hPCDH1) cultured in 5i/
L/FA conditions was consistently lower (but not absent) than for
primed state hESC (less so for hPCDH1) or hiPSC. These results
also indicate phenotypic differences between the hPSCs cultured
in 5i/L/FA conditions and NHSM or RSeT cultured naive hPSCs.
The NHSM cells showed very similar phenotypic immunoreactivi-
ty to the mAbs when compared to primed hPSCs whereas RSET
cells show lower percentages of immunoreactivity to three mAbs
(hCDH3, hNLGN4X, & hPCDH1) than primed cells (although not as
low as 5i/L/FA cultured cells). It is interesting to speculate that
loss of immunoreactivity to the four mAbs (hGPR64, hCDH3,
hNLGN4X, & hPCDH1) indicates progression from a primed cell
state to a more naive state but further experimentation is needed
to determine whether loss of the epitopes detected by the mAbs
is intrinsic to naive cells or not. The results also clearly indicate
that three mAbs (hCDCP1, hF11R, & hDSG2) consistently stain
greater than 80% of the cells cultured in naive or primed condi-
tions. Collectively, these results demonstrate heterogeneity with-
in naive cells produced using different culture methodologies.
Pastor et al. (2016) [39] report that a subpopulation of SSEA-4
negative cells more closely resemble the human preimplantation
epiblast than do SSEA-4 positive cells [57]. We, therefore, further
Figure 2. New monoclonal antibodies (mAbs) enable live cell
detection and culture of self-renewing human pluripotent stem
cells (hPSCs). For undifferentiated hPSC cultures immunolabeled
with new purified mAbs anti-hGPR64, anti-hCDCP1, anti-hF11R,
anti-hDSG2, anti-hCDH3, anti-hNLGN4X, anti-hPCDH1 (A) Repre-
sentative flow cytometric histogram plots showing live cell fluo-
rescence detection (AF488) of protein epitopes corresponding to
all mAbs for a high percentage (%) of total MEL1 cells analyzed
(hiPS-NHF1.3 cells for anti-hGPR64), (red histogram), against iso-
type controls (gray histogram). (B): Representative flow cytomet-
ric dot plots showing high coexpression of mAb detected hPSC-
surface proteins (AF488) and OCT4 (AF647) against isotype con-
trols following sequential live and fixed cell immunolabeling of
hiPS-NHF1.3 cells (anti-hGPR64) and WA09 cells (all other mAbs).
(C): Multicolor immunostaining and flow cytometric replicate
analyses shown graphically for the live cell codetection (mean %)
of human iPS cells-HDF32f cells by each mAb with the TRA-1-60
or SSEA-4 pluripotency-associated antibodies, compared with iso-
type controls (not shown). Bars represent the mean percentage
of cells staining positively for each mAb within the TRA-1-60 or
SSEA-4 positive cell population (n 5 3, mean 1/2 SEM). (D): Tri-
ple color flow cytometric analyses demonstrates varying coexpres-
sion profiles of each mAb with the GCTM-2/CD9 gradient in hPSC
cultures; (i) Representative flow cytometric analysis for GCTM-2
(AF647) and CD9 (AF488) coexpression gradient in live MEL1 cell
cultures. Population gates are set against isotype controls for neg-
ative (GCTM-2-AF647-/CD9-AF488- blue gate) and high (GCTM-2-
AF647hi/CD9-AF488hi yellow gate) cells; (ii) Representative flow
cytometric histogram plots showing the percentage of mAb-
detected cells overlapping with the GCTM-2/CD9 high (yellow)
and negative (blue) populations against isotype controls (gray).
(E): Colony-forming assays (CFAs) for the postfluorescence activat-
ed cell sorting (FACS) culture (5,000 cells/3.8cm2 well) of hiPS-
NHF1.3 cells gated for replating the top 25% (FACS bright25%hi,
orange bars) and ungated (gray bar) cells detected by mAbs com-
pared with CD9, GCTM-2, TRA-1-60, SSEA-4, and UEA-1 lectin; (i)
Mean colony counts per well after 5 days culture in hPSC condi-
tions (n 5 3). (ii) Percentage OCT4-AF647 positive cells detected
by flow cytometry for the preceding CFAs harvested at 7 days of
post-FACS culture for FACS bright25%hi (orange bars) and ungated
(gray bar) cells (n 5 3). All Error bars depict SEM. Abbreviation:
hPSCs, human pluripotent stem cells.
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Figure 3. Cell surface antigens are detected on naive state human pluripotent cells. Transcriptional and protein analyses showing the expression of
cell surface epitopes on human iPS cells (hiPSCs) and human ES cells (hESCs) cultured in conditions supporting a naive state of pluripotency. (A):
Schematic depicting the generation of naive human cell cultures both from lineage primed hiPSCs and blastocyst epiblast cells. Human dermal fibro-
blasts (HDFs) were reprogrammed to primed hiPSCs in standard human pluripotent stem cell (hPSC)-MEF culture then coaxed to a naive pluripotent
state in NHSMa, RSET, and 5i/L/FAb defined media-MEF supported culture conditions. Naive state hESCs were derivedc and maintained following the
direct culture of preimplantation blastocyst in 5i/L/FA-MEF conditions. (B): PCA of RNA sequencing data for the primed and naive (5i/L/FA) state
hiPSCs from this study and the microarray data extracted from the published report of Theunissen et al. (2014), [38] confirms differential clustering
of two parental HDFs (black dot), lineage primed hiPSCs from this study (dark blue dot) and Theunissen et al. (2014), (light blue dot), and naive
hiPSCs from this study (dark yellow dot) clustering with the naive hiPSCs from Theunissen et al. (2014) (gold dot). (C): Representative images for
naive hiPSC colonies originating from two parental HDF cell lines (HDF32f, HDF55f) following culture in NHSMa-MEF, RSeT-MEF, and 5i/L/FAb-MEF
conditions and preimplantation blastocyst-derived hES naive cell colonies (UCLA20nc) generated directly in 5i/L/FA-MEF culture conditions. HiPS and
hESC naive cell cultures show a domed colony morphology by bright field phase contrast microscopy (BF). (D): Flow cytometric replicate analyses
shown graphically for the live cell detection of naive state hiPS-HDF32f cells maintained on MEFs in NHSMa, 5i/L/FAb, and RSeT culture media, and
naive UCLA20n hESCs in 5i/L/FA-MEF culture, by the monoclonal antibodies anti-hGPR64 (light blue bars), anti-hCDCP1 (orange bars), anti-hF11R
(gray bars), anti-hDSG2 (yellow bars), anti-hCDH3 (mid blue bars), anti-hNLGN4X (green bars), anti-hPCDH1 (dark blue bars), compared with lineage
primed WA09 cells (hESC primed) and parental hiPS-HDF32f cells (hiPSC primed) cultured on MEFs in hPSC medium, against isotype controls (not
shown), (n 5 3, except UCLA20n in 5i/L/FA n 5 2). Error bars depict SEM. Scale bars5 500 mm (white) and 200 mm (black) for BF images. aGafni O
et al. Nature 2013;504:282-286. bTheunissen TW et al. Cell Stem Cell 2014;15:471-487. cPastor WA et al. Cell Stem Cell 2016;18:323-329. Abbrevia-
tions: hESCs, human ES cells; hiPSCs, human iPS cells.
examined the immunoreactivity of each or our new mAbs with
SSEA-4 negative populations from 5i/L/FA cultured naive hiPSC
(Supporting Information Fig. S6). Note the UCLA20n line is essen-
tially SSEA-4 negative (data not shown), as previously reported
[39], and can, therefore, also be analyzed for comparison (Fig.
3D). The comparison of the SSEA-4 negative population with the
SSEA4 positive population of 5i/L/FA cultured naive hiPSCs and
the UCLA20n cells indicates similar patterns of immunoreactivity
implying that our new mAbs are not able to distinguish between
these two populations (Supporting Information Fig. S6). Never-
theless, the above set of results examining human naive cell pop-
ulations indicate that the new mAbs described herein will likely
be useful tools for subfractionating these cell populations for fur-
ther study of heterogeneity within naive states of human pluripo-
tency and for studying differences between naive cells produced
using distinct culture methodologies.
Ability of New mAbs to Detect HPSCs During EB
Differentiation
Next, we assessed the immunoreactivity to cell-surface proteins
detected by each mAb in hPSC cultures undergoing spontaneous
in vitro EB-based differentiation, determined at 0, 7, 14, and 28
days. Flow cytometric analyses for each mAb in differentiation
cultures for two hESC and two hiPSC lines were compared with
CD9, TRA-1-60, UEA-1, and OCT4 (Fig. 4A) and demonstrated a
change in the percentage of cells displaying immunoreactivity of
all hPSC markers but with differing kinetics seen over the time
course. Concordant with the ability to detect GCTM-2neg/CD9neg
cells in differentiating hPSC cultures (Fig. 2D, i-ii, Supporting
Information Fig. S4), the F11R, DSG2, and GRP64 mAbs dis-
played an expression profile in differentiating cultures that is
downregulated but less rapidly than for the CDCP1, CDH3,
NLGNX4, and PCDH1 mAbs, which show profiles comparative to
those for OCT4, TRA-1-60, SSEA-3, GCTM-2, and UEA-1 markers.
CD9, after an initial downregulation at 7 days, retained the high-
est cell detection of all markers analyzed in this time course
study, consistent with its known expression in epithelial cells
[58]. We further interrogated the flow cytometric analyses for
EB cultures to determine the percentage of cells codetected by
each marker of the OCT4-labeled population at each time point
(Fig. 4B, Supporting Information Table S3). Note this population
becomes increasingly rarer over time. Following a rapid decline
in OCT4 expression after 7 days differentiation for all cell lines,
those mAbs displaying decreased but lingering detection of cell-
surface proteins after 28 days of differentiation (F11R, DSG2,
GPR64, Fig. 4A) were also detecting the high percentages of
residual OCT4-positive cells. This underscores the potential
ability of these three mAbs to remove unwanted residual OCT4-
positive cells from mixed differentiated cell populations.
Broader Utility of New mAbs
The cell-surface proteins in this study are all known for biologi-
cal profiles that are of interest because of their association with
development and disease states. Some of these markers are
predicted to be misregulated in the onset of some types of can-
cers [59, 60]. As one example, the F11R protein (also known as
JAM-A) is known to be critical for tight junction functioning in
the developing blastocyst [61], and is implicated in regulating
the migration of endothelial cells in the progression of various
human malignancies including breast, gastric, and lung tumours
[62–64]. In addition, these proteins have interesting tissue- and
cancer-specific expression profiles reported in the The Human
Protein Atlas [65] (http://www.proteinatlas.org). These specific
expression patterns indicate that the mAbs developed in this
study will be useful tools for examination of a range of human
developmental processes and diseases.
We investigated the utility of the new pluripotency-
associated mAbs to interrogate detection or absence of epitopes
expressed on MSCs derived from human bone marrow, and on
epithelial and stromal cell populations isolated from human
breast and epithelial cell populations from colon tissues. For
hBM-MSC cultures confirmed for a CD901 phenotype, we found
the anti-hCDCP1 mAb detected the antigen on a subset of cells
(50.2%6 SD 8.1%, data not shown). The CDCP1 antigen has
been previously reported to be expressed in normal epithelial
cells, overexpressed in proliferating epithelial tumors such as
colon, breast, lung, renal cancers [66–68], and is suggested as a
potential therapeutic target for pancreatic tumor cell migration
and metastasis [69]. More recently, CDCP1 is reported to be
expressed on a functionally distinct CD146neg subset of marrow
fibroblasts that may play a role in regulating hematopoietic
cytokine expression [70].
Our study identified three antigens (CDCP1, F11R, and
DSG2) that were highly expressed by human mammary epitheli-
al cells following FACS into four unique subsets:- luminal pro-
genitor (CD49f1 EpCAM1), mature luminal (CD49f2EpCAM1),
MaSC and basal (CD49f1 EpCAM2) and fibroblast-enriched
stromal (CD49f2EpCAM2), (Fig. 5A, i-ii). The luminal progenitor
subset highly expressed F11R (99.9%6 0.1%), DSG2 (98.7%6
0.7%), and CDCP1 (95.9%6 3.0%) and expressed low levels of
NLGN4X (5.7%6 4.1%) and CDH3 (4.3%6 1.3%). The mature
luminal subset highly expressed F11R (98.6%6 2.7%), DSG2
(95.8%6 2.2%) and CDCP1 (96.2%6 3.6%), and low levels of
CDH3 (1.0%6 0.3%). The MaSC/basal subset highly expressed
F11R (90.4%6 10.7%) and DSG2 (96.5%6 0.8%) and expressed
CDCP1 to some extent (55.3%6 32.7%) as well as weak expres-
sion of CDH3 (4.0%6 3.7%). The fibroblast-enriched stromal
population expressed very low levels (2.7%6 1.8%) of F11R on
cells and was devoid of all other antigens. Our mAbs did not
detect PCDH1 nor GRP64 expression on any of the human breast
epithelial or stromal subsets (Fig. 5A, ii, [5]B). Collectively these
results show the ability of the pluripotency-associated anti-
bodies to specifically discern antigen expression on human
breast epithelial and stromal subpopulations and raise the pos-
sibility that these antigens may have potential as biomarkers for
breast cancer. Extending from the above reports exemplifying
CDCP1 overexpression on cancerous epithelial cells from multi-
ple tissues [66–69], a recent study indicates CDCP1 as a modula-
tor of HER2 signaling, an interaction that results in increased
tumor formation and cell migration as well as c-SRC mediated
resistance to trastuzumab in HER2-positive breast cancer
patients [71]. F11R is reported to be expressed in the luminal
and basal cells of normal human breast tissue and is overex-
pressed in breast tumours, in which it correlates with a poor
prognosis [72–74]. The downregulation of F11R expression in
murine and human mammary tumor models has been shown to
reduce tumor proliferation by increasing cell susceptibility to
apoptosis [73, 74]. DSG2 is a key glycoprotein found in the
desmosomes of epithelial junctions and is localized to both the
luminal and myoepithelium of normal breast tissue [75]. As
most solid cancers are of epithelial origin, DSG2 is consistently
upregulated in most cancers analyzed [65]. The maintenance of
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Figure 4. New monoclonal antibodies (mAbs) determine downregulation of cell surface epitopes during human pluripotent stem cells
(hPSC) differentiation. (A): Flow cytometric replicate analyses shown graphically for the detection of live cells by immunostaining with
purified mAbs in differentiating embryoid body (EB) cultures for hPSC lines MEL1 (blue plotted lines), WA09 (red plotted lines), hiPS-
NHF1.3 (green plotted lines), hiPS-PDL-D1C6 (purple plotted lines) on the day of harvesting routine undifferentiated cultures (day 0),
and following induction of differentiation in EB suspension cultures (days 7, 14, 28). Comparative analyses show detection of live cells
for the same cultures and time points using CD9, TRA-1-60, GCTM-2, and biotinylated UEA-1 lectin, and fixed cell detection for OCT4
(n 5 3). (B): For the analyses shown in (A), data displayed graphically for % of total residual OCT4-positive cells detected by each mAb
and pluripotency associated marker in differentiating cultures for each cell line at each time point (n 5 3). All error bars depict SEM.
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Figure 5. Expression of pluripotency-associated antigens in human breast tissue and on normal and cancerous intestinal epithelial cells.
(A): Human CD312CD452CD235a2 cell populations isolated from mammary tissue were (i) fluorescence activated cell sorting (FACS)-
delineated using EpCAM and CD49f to resolve each of the four breast epithelial cell subsets:- luminal progenitor (CD49f1 EpCAM1),
MaSC and basal (CD49f1 EpCAM2), mature luminal (CD49f2EpCAM1), and fibroblast-enriched stromal (CD49f2EpCAM2); (ii) Represen-
tative flow histogram plots show the presence or absence of antigens detected by the purified monoclonal antibodies (mAbs) anti-
hGRP64, anti-hCDCP1, anti-hF11R, anti-hDSG2, anti-hCDH2, anti-hNLGN4X, and anti-hPCDH1 in these cell subsets, compared with isotype
controls. (B): Bar graphs show the detection of pluripotency-associated antigens for mammary cell subsets from four donor specimens
as mean 1/2 SEM across two technical replicates compared with isotype controls and NHF1-3 hiPS positive control cells. (C): (i) Human
intestinal epithelial cells were isolated from normal and cancerous colorectal tissues by FACS selection for EpCAM1 CD312CD452 cells.
(ii) Bar graphs show the variation in detection of pluripotency-associated antigens by the panel of mAbs (A-B) on normal and cancerous
intestinal epithelial cells from three patient donor samples compared with isotype controls. Abbreviation: hiPSCs, human iPS cells.
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intercellular junctions in both normal epithelial and tumor tis-
sues acts to prevent host immune responses and creates a barri-
er that prevents the effective dissemination of cancer
therapeutics [76].
Our analyses of an enriched EpCAM1 (CD452CD312) intes-
tinal epithelial (IE) cell population [43] (Fig. 5C, i) isolated from
the normal colon and colorectal cancer tissues of three patients
demonstrated firstly, the overall reduction in IE cell retrieval
from cancerous tissues, and second, the detection to varying
degrees of all epitopes on normal IE cells corresponding to the
panel of pluripotency mAbs, excepting the very low expression
of PCDH1 for two patient IE populations (Fig. 5C, ii). While
detected antigen expression is variable between donor patient
tissues (Fig. 5C, ii), the complete maintenance of upregulated
CDCP1 and F11R expression in both normal and cancerous IE
populations, is consistent with the aggressive proliferation of
tumor cells in colorectal cancer [66–68], and the maintenance
of tight junctions in both normal and dedifferentiated epithelial
tumor cells [76]. Interestingly, downregulation of DSG2 expres-
sion was demonstrated for the cancerous IE cells from all
patients compared with their corresponding normal tissue IE
populations. Markers detected in cell subsets of the normal IE
populations of all patients (GRP64, CDH3, NLGN4X, and PCDH1)
displayed a trend for downregulation in corresponding tumor IE
cell samples, except for one patient’s samples displaying some
upregulation of NLGN4X (Fig. 5C, ii). NLGN4X is an adhesion
molecule involved in neuronal cell adhesion and synaptic forma-
tion and function [77], with various mutations of the encoding
gene being implicated in autism spectrum disorders [78].
Evidence for NLGN4X expression in normal colorectal tissue is
reported, but its overexpression in tumors is to date associated
principally with gliomas, ovarian, endometrial, breast, and uroe-
pithelial cancers [65]. Collectively, these studies indicate the
utility of antibody-based in vitro interrogation of both normal
developmental events and the exploration for biomarkers
applicable to the stratification of individual patients in treating a
wide range of cancers.
While published genomic- and proteomic-based studies
have previously identified some of these candidate extracellular
hPSC markers [13, 59], to date the existing antibodies for these
proteins, many of which are polyclonal, have not been demon-
strated to effectively detect epitopes on live hPSCs. Since the
mAbs reported in this study have been raised to known protein
antigens and all were specifically screened for detection on live
hPSCs, these mAbs provide a greatly expanded resource for a
variety of applications, including purification of subpopulations,
removal of unwanted cells from differentiating hPSC derivatives,
and detailed study of the nature of pluripotency.
CONCLUSION
In conclusion, we report the generation of a panel of new
mAbs that can efficiently detect the presence of cell-surface
epitopes on viable human embryonic and induced pluripotent
stem cells. Moreover, we demonstrate that our new panel of
antibodies detect the expression of these proteins on subsets
of human cells when derived using naive conditions or reset
in vitro to a naive pluripotent state [29, 39, 56]. We anticipate
that the novel antibodies generated and validated in this
study will be valuable tools for studying human pluripotency,
cellular reprogramming and differentiation, and for develop-
ment of strategies enabling stringent quality control of live
hPSC-derived cell populations destined for clinical use.
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